Clinical Trial Update: Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the nicotine vaccine NIC002 in smokers motivated to quit has completed, assessing efficacy, safety, tolerability and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• NIC002 vaccine (nicotine vaccine NIC002)

Snippet

Sponsor: Novartis | Conditions: Smokers | Phase 2 | Status: COMPLETED